Antiplatelet and antithrombin therapy for early management of acute coronary syndromes

Journal of Pharmacy Practice

Volumn 17, Issue 5, 2004, Pages 347-369

  Wiggins, Barbara S ^a,b,c   Spinler, Sarah ^d,e  

^a Heart Center   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Abciximab; Acute coronary syndromes; Antiplatelet; Aspirin; Bivalirudin; Clopidogrel; Enoxaparin; Eptifibatide; Low molecular weight heparin; UFH

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PROSTAGLANDIN SYNTHASE; STREPTOKINASE; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE HEART FAILURE; ANAPHYLAXIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERANCE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; META ANALYSIS; NEUTROPENIA; PRACTICE GUIDELINE; RASH; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 10644234807     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004271778     Document Type: Review

References (127)

1. American Heart Association. Heart Disease and Stroke Statistics: 2004 Update. Dallas, Tex: American Heart Association National Center; 2003.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
3. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
4. Kristensen SD, Ravn HB, Falk E. Insights into the pathophysiology of unstable coronary artery disease. Am J Cardiol. 1997;80(5A):5E-9E.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326(4):242-249.
6. Dobesh PP, Latham KA. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb/IIIa inhibitors. Pharmacotherapy. 1998;18:663-685.
7. Chong PH. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Am J Health Syst Pharm. 1998;55:2363-2386.
8. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Paul Dudley White Lecture 1995. Circulation. 1996;94:2013-2020.
9. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). J Am Coll Cardiol. 2001;37:2215-2239.
10. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
11. Antman EM, Anbe DT, Armstrong PW, et al. 2004 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Available at: www.acc.org/clinical/guidelines/stemi/index.pdf.
12. Spinler SA. Acute coronary syndromes. In: Zarowitz B, Brundage D, Chessman K, et al, eds. Pharmacotherapy Self-Assessment Program: Book 1 - Cardiovascular I Cardiovascular II. 5th ed. Kansas City, Kan: American College of Clinical Pharmacy; 2004.
13. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
14. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.
15. Topol EJ. Current status and future prospects for acute myocardial infarction therapy. Circulation. 2003;108(suppl III):6-13.
16. Bell WR. Present-day thrombolytic therapy: therapeutic agents - pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3(suppl 2):S34-44.
17. Lip GYH, Chin BSP, Prasad N. Antithrombotic therapy in myocardial infarction and stable angina. BMJ. 2002;325:1287-1289.
18. Spinler SA. Acute coronary syndromes. In: Bertch K, Dunsworth T, Fagan S, et al, eds. Pharmacotherapy Self-Assessment Program: Book 1 - Cardiovascular I Cardiovascular II. 4th ed. Kansas City, Kan: American College of Clinical Pharmacy; 2001:157-190.
19. Fox KAA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002;360:743-751.
20. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
21. Sabatine MS, Antman EM. The Thrombolysis in Myocardial Infarction Risk Score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;41:89S-95S.
22. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
23. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68:11B-15B.
24. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;72:3073-3076.
25. Pitt B, Shae MJ, Romson JL. Prostaglandings and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med. 1983;99:83-92.
26. Schror K. Antiplatelet drugs: a comparative review. Drugs. 1995;50:7-28.
27. Fuster V, Dyken ML, Vokanas PS, Hennekens C. AHA medical scientific statement: special report. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
28. Massotti G, Galanti G, Poggesi L, Abbate R, Neri S. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979;2:1213-1217.
29. Tisdale JE. Antiplatlet therapy in coronary artery disease: review and update of efficacy studies. Am J Health Syst Pharm. 1998;55(suppl 1):S8-S16.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
31. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk of unstable angina. J Am Coll Cardiol. 2001;37:1266-1270.
32. Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol. 2003;92:843-845.
33. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid: a protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
34. Morrow DA, Rifai N, Antman E, et al. C-reactive protein in a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460-1465.
35. Feldman M, Ishwarlol J, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001;37:2036-2041.
36. Azar RR, Klayme S, Germanos M, et al. Effects of aspirin (325 mg/day) on serums high sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol. 2003;92:236-239.
37. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309:396-403.
38. Cains JA, Gent M, Singer J, et al. Aspirin, sulfmpyrazone, or both in unstable angina. N Engl J Med. 1985;313:1369-1375.
39. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
40. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
41. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
43. Hirsh J. The optimal antithrombotic dose of aspirin. Arch Intern Med. 1985;145:1582.
44. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
45. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
46. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ. 1999;319:630-635.
47. Lauer MS. Clinical practice: aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468-1474.
48. Peters RJG, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogiel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
49. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406.
50. Mueller JE, Braumwald E. Can infarct size be limited in patients with acute myocardial infarction? Cardiovasc Clin. 1983;69:740-747.
51. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983;74(suppl 6A):102-109.
52. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
53. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke. 1993;24:345-350.
54. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function: implications for clinical trials and therapy. Arch Pathol Lab Med. 1994;118:801-804.
55. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients: evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 1991;63:587-593.
56. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet activity. Circulation. 1998;97:350-355.
57. Gum PA, Kottke-Merchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
58. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993;11:180-198.
59. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
60. Yao SK, McNatt J, Cui K, Anderson HV. Combined ADP and thromboxane A2 antagnoism prevents cyclic flow variations in stenosed and endothelium injured arteries in non human primates. Circulation. 1993;88:2888-2893.
61. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs. 1990;40:239-259.
62. Bachmann F, Savcic M, Hauert J, Geudelin B. Rapid onset of inhibition of ADP induced platelet aggregation by a loading dose of clopidogrel [abstract]. Eur Heart J. 1996;17:263.
63. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93.
64. Savcic M, Hauert J, Bachman F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamics response in healthy subjects. Semin Thromb Hemost. 1999;25(suppl 2):15-19.
65. Cadroy Y, Bossavy JP, Thalamus C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental thrombogenesis in humans. Circulation. 2000;101:2823-2828.
66. Ishikawa K, Kanamasa K, Hama J, et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Jpn Circ J. 1997;61:38-45.
67. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. Circulation. 1990;82:17-26.
68. Hall P, Nakamura KS, Maiello L. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
69. Schomig A, Neumann FJ, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;33:1084-1089
70. Leon MB, Baim DS, Popma JJ, et al, for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
71. Bertrand ME, Rupprect HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624-629.
72. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9-14.
73. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1999;348:1329-1339.
74. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
75. Mehta SR, Yusuf S, Peters RJ, et al, for the CURE Investigators. Effects of pretreatement with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
76. Steinhubl SR, Berger PB, Mann JT, et al, for the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
77. Kastrati A, Mehilli J, Schuhlen H, et al, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-238.
78. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-972.
79. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
80. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
81. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaunessy C, Tift Mann J. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
82. Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet. 1997;349:474-475.
83. Majhail NS, Lichtin AE. Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality. Cleve Clin J Med. 2003;70:466-470.
84. Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
85. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2372-2380.
86. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
87. O'Shea JC, Håfley GE, Greenberg S, et al, ESPIRIT investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial - a randomized controlled trial. JAMA. 2001;285:2468-2473.
88. The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
89. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
90. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
91. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms (PRISM-PLUS) Study investigators. Inhibition of the platelet glycoprotein IIa/IIIb receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
92. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
93. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol. 2004;93:830-835.
94. Brener SJ, Zeymer U, Adgey AAJ, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The Integrelin and Low-dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) Trial. J Am Coll Cardiol. 2002;39:377-386.
95. Roe MT, Green CL, Giugliano RP, et al. Improved speed and stability of ST-segment recovery with reduced dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;43:549-556.
96. Martinez-Rios MA, Rosas M, Gonzalez H, et al, for the SASTRE investigators. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol. 2004;93:280-287.
97. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362-366.
98. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angtioplasty. N Engl J Med. 1994;330:956-961.
99. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronay revascularization. N Engl J Med. 1997;336:1689-1696.
100. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 1998;352:87-92.
101. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140:206-211.
102. Wagner CL, Cunningham MR, Wyand MS, et al. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys [abstract]. Thromb Haemost. 1995;73:1313.
103. Li YF, Spencer FA, Becker RC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (IIb/β3) receptor-directed platelet inhibition. Am Heart J. 2001;42:204-210.
104. Morange PE, Simon C, Alessi MC, et al. Endothelial cell markers and the risk of coronary heart disease: the prospective epidemiological study of myocardial infarction (PRIME) study. Circulation. 2004;109:1343-1348.
105. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatment on von Willebrand factor release in unstable angina. J Am Coll Cardiol. 2000;36:110-114.
106. Gori AM, Fedi S, Pepe G, et al. Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term and low molecular weight heparin administration. Br J Haematol. 2002;117:693-698.
107. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996;276:811-815.
108. Low-molecular-weight heparin during instability in coronary artery disease. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996;347:561-568.
109. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). [published correction appears in Circulation. 1998;97:413]. Circulation. 1997;96:61-68.
110. Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
111. Antman EM, McCabe CH, Gurfinkel EP, et al, for the TIMI 11B investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593-1601.
112. The SYNERGY Trial investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
113. Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol. 2003;91:860-864.
114. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135-142.
115. Newby LK, Harrington RA, Bhapkar MV, et al. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002;14:33-42.
116. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, for the ESSENCE and TIMI 11B investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33-41.
117. Thorevska N, Amoateng-Adjepong Y, Sahahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparing of bleeding rtes with unfractionated heparin versus enoxaparin. Chest. 2004;125:856-863.
118. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001;119(suppl):64S-94S.
119. Wiggins BS, Spinler S, Wittkowsky AK, Stringer KA. Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. Pharmacotherapy. 2002;22:1007-1018.
120. The Hirulog and Early Reperfusion or Occlusions (HERO)-2 investigators. Thrombin specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERE-2 randomised trial. Lancet. 2001;358:1855-1863.
121. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial [published correction appears in JAMA. 2003;289:1638]. JAMA. 2003;289:853-863.
122. The ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. Available at: http://www.ihcresearch.com/ACUITYOverviewweb.pdf. Accessed April 6, 2004.
123. Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm. 2003;60:1841-1849.
124. Simoons ML, Bobbink IWG, Boland J, Gardien M, Klootwijk P, Lensing AWA. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acuty coronary syndromes. The Pentasaccharide in Unstable Angain (PENTUA) Study. J Am Coll Cardiol. 2004;43:2183-2190.
125. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE Study. Eur Heart J. 2001;22:1716-1724.
126. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003;109:1-11.
127. The OASIS-5 and OASIS-6 Trials. Available at: http://www.sanofi-synth.cz/ press010403_aj.htm. Accessed April 6, 2004.